520880 港股通创新药ETF
已收盘 12-05 14:59:57
资讯
新帖
简况
全球创新药研发提速,港股创新药强劲反弹,100%创新药研发标的“520880”冲高2%!
新浪基金 · 11-20
全球创新药研发提速,港股创新药强劲反弹,100%创新药研发标的“520880”冲高2%!
【ETF动向】11月19日汇添富国证港股通创新药ETF基金跌0.62%,份额增加1.21亿份
证券之星 · 11-20
【ETF动向】11月19日汇添富国证港股通创新药ETF基金跌0.62%,份额增加1.21亿份
【ETF动向】11月17日汇添富国证港股通创新药ETF基金跌1.43%,份额增加1.14亿份
证券之星 · 11-18
【ETF动向】11月17日汇添富国证港股通创新药ETF基金跌1.43%,份额增加1.14亿份
【ETF动向】11月13日汇添富国证港股通创新药ETF基金涨4.99%,份额增加2.76亿份
证券之星 · 11-14
【ETF动向】11月13日汇添富国证港股通创新药ETF基金涨4.99%,份额增加2.76亿份
【ETF动向】11月5日银华国证港股通创新药ETF基金跌0.47%,份额增加1.63亿份
证券之星 · 11-06
【ETF动向】11月5日银华国证港股通创新药ETF基金跌0.47%,份额增加1.63亿份
【ETF动向】11月3日南方国证港股通创新药ETF基金涨2.03%,份额增加7600万份
证券之星 · 11-04
【ETF动向】11月3日南方国证港股通创新药ETF基金涨2.03%,份额增加7600万份
半年线支撑显现,港股通创新药ETF(520880)盘中再起溢价!行情拐点将至?
新浪基金 · 10-27
半年线支撑显现,港股通创新药ETF(520880)盘中再起溢价!行情拐点将至?
银华基金马君旗下银华国证港股通创新药ETF三季报最新持仓,重仓百济神州
证券之星 · 10-27
银华基金马君旗下银华国证港股通创新药ETF三季报最新持仓,重仓百济神州
【ETF动向】10月22日银华国证港股通创新药ETF基金跌2.86%,份额增加1.02亿份
证券之星 · 10-23
【ETF动向】10月22日银华国证港股通创新药ETF基金跌2.86%,份额增加1.02亿份
景顺长城中证港股通创新药ETF基金经理变动:张晓南不再担任该基金基金经理
证券之星 · 10-22
景顺长城中证港股通创新药ETF基金经理变动:张晓南不再担任该基金基金经理
114亿美元!中国创新药BD新纪录!高弹性港股通创新药ETF(520880)热度飙升
新浪基金 · 10-22
114亿美元!中国创新药BD新纪录!高弹性港股通创新药ETF(520880)热度飙升
【ETF动向】10月21日易方达恒生港股通创新药ETF基金涨1.24%,份额增加1.31亿份
证券之星 · 10-22
【ETF动向】10月21日易方达恒生港股通创新药ETF基金涨1.24%,份额增加1.31亿份
港股通创新药回暖,520880涨1.21%溢价飙升!基金经理:创新药行情或将重回“质量”驱动,龙头有望胜出
新浪基金 · 10-21
港股通创新药回暖,520880涨1.21%溢价飙升!基金经理:创新药行情或将重回“质量”驱动,龙头有望胜出
医药资产又香了?近7亿资金增仓医疗ETF(512170)!港股通创新药ETF(520880)连日高溢价
新浪基金 · 10-19
医药资产又香了?近7亿资金增仓医疗ETF(512170)!港股通创新药ETF(520880)连日高溢价
【ETF动向】10月16日南方国证港股通创新药ETF基金涨2.19%,份额增加1亿份
证券之星 · 10-17
【ETF动向】10月16日南方国证港股通创新药ETF基金涨2.19%,份额增加1亿份
第二波行情启动?高弹性港股通创新药ETF(520880)冲高3.6%!映恩生物-B、三生制药、康方生物集体飙升
新浪基金 · 10-16
第二波行情启动?高弹性港股通创新药ETF(520880)冲高3.6%!映恩生物-B、三生制药、康方生物集体飙升
港股真香,齐刷刷上涨!港股ETF三剑客520560、513770、520880带头冲锋突围
市场资讯 · 10-16
港股真香,齐刷刷上涨!港股ETF三剑客520560、513770、520880带头冲锋突围
AH医药再陷调整,医疗ETF止步三连阳,港股通创新药ETF(520880)失守所有均线,该抄底还是离场?
新浪基金 · 10-12
AH医药再陷调整,医疗ETF止步三连阳,港股通创新药ETF(520880)失守所有均线,该抄底还是离场?
风险还是机遇?AH医药集体杀跌!药明康德重挫,医疗ETF下穿3根均线!创新药反攻未果,520880溢价飙逾1%
新浪基金 · 10-10
风险还是机遇?AH医药集体杀跌!药明康德重挫,医疗ETF下穿3根均线!创新药反攻未果,520880溢价飙逾1%
【ETF动向】10月9日易方达恒生港股通创新药ETF基金跌1.26%,份额增加1亿份
证券之星 · 10-10
【ETF动向】10月9日易方达恒生港股通创新药ETF基金跌1.26%,份额增加1亿份
加载更多
公司概况
公司名称:
--
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"520880","market":"SH","secType":"STK","nameCN":"港股通创新药ETF","latestPrice":0.558,"timestamp":1764917997000,"preClose":0.558,"halted":0,"volume":293671400,"delay":0,"changeRate":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0,"latestTime":"12-05 14:59:57","open":0.558,"high":0.561,"low":0.552,"amount":163000000,"amplitude":0.0161,"askPrice":0.559,"askSize":70967,"bidPrice":0.558,"bidSize":34337,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":0.558,"symbolType":"fund","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":0.614,"lowLimit":0.502,"ibTradeSell":false,"ibTradeBuySell":false,"isCdr":false,"pbRate":0,"committee":-0.266986,"marketValue":0,"turnoverRate":0,"status":2,"floatMarketCap":0},"requestUrl":"/m/hq/s/520880","defaultTab":"news","newsList":[{"id":"2584346905","title":"全球创新药研发提速,港股创新药强劲反弹,100%创新药研发标的“520880”冲高2%!","url":"https://stock-news.laohu8.com/highlight/detail?id=2584346905","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584346905?lang=zh_cn&edition=full","pubTime":"2025-11-20 10:17","pubTimestamp":1763605020,"startTime":"0","endTime":"0","summary":"连跌4日后,港股创新药终于迎来反弹!11月20日早盘,100%创新药研发标的——港股通创新药ETF高开后一度冲高2%,盘中收复10日均线。场内溢价频现,彰显买盘势力。 消息面,近期全球创新药研发密集迎新进展。 把握创新药新一轮配置窗口,首选同类最大港股通创新药ETF及其场外联接基金,标的指数恒生港股通创新药精选指数具备三大独特优势:","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-11-20/doc-infxzepk1110570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1161","BK1574","520880"],"gpt_icon":0},{"id":"2584958972","title":"【ETF动向】11月19日汇添富国证港股通创新药ETF基金跌0.62%,份额增加1.21亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2584958972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584958972?lang=zh_cn&edition=full","pubTime":"2025-11-20 08:02","pubTimestamp":1763596920,"startTime":"0","endTime":"0","summary":"证券之星消息,11月19日,汇添富国证港股通创新药ETF基金(159570)跌0.62%,成交额24.27亿元。当日份额增加了1.21亿份,最新份额为132.87亿份,近20个交易日份额增加15.41亿份。当日资金净流入4942.6万元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为232.09亿元。汇添富国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2023-12-28)以来超额回报为-34.21%,近一个月超额回报为-0.23%,管理人为汇添富基金公司,基金经理为乐无穹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000003555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2584060336","title":"【ETF动向】11月17日汇添富国证港股通创新药ETF基金跌1.43%,份额增加1.14亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2584060336","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584060336?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:02","pubTimestamp":1763424120,"startTime":"0","endTime":"0","summary":"证券之星消息,11月17日,汇添富国证港股通创新药ETF基金(159570)跌1.43%,成交额22.33亿元。当日份额增加了1.14亿份,最新份额为131.64亿份,近20个交易日份额增加13.59亿份。当日资金净流出2.83亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为235.39亿元。汇添富国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2023-12-28)以来超额回报为-39.31%,近一个月超额回报为-2.27%,管理人为汇添富基金公司,基金经理为乐无穹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800004980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2583545412","title":"【ETF动向】11月13日汇添富国证港股通创新药ETF基金涨4.99%,份额增加2.76亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2583545412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583545412?lang=zh_cn&edition=full","pubTime":"2025-11-14 08:01","pubTimestamp":1763078518,"startTime":"0","endTime":"0","summary":"证券之星消息,11月13日,汇添富国证港股通创新药ETF基金(159570)涨4.99%,成交额42.97亿元。当日份额增加了2.76亿份,最新份额为128.94亿份,近20个交易日份额增加10.91亿份。当日资金净流入15.32亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为236.4亿元。汇添富国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2023-12-28)以来超额回报为-35.48%,近一个月超额回报为0.13%,管理人为汇添富基金公司,基金经理为乐无穹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400005136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2581081845","title":"【ETF动向】11月5日银华国证港股通创新药ETF基金跌0.47%,份额增加1.63亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581081845?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:01","pubTimestamp":1762387319,"startTime":"0","endTime":"0","summary":"证券之星消息,11月5日,银华国证港股通创新药ETF基金(159567)跌0.47%,成交额17.14亿元。当日份额增加了1.63亿份,最新份额为94.22亿份,近20个交易日份额增加12.79亿份。当日资金净流入1.76亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为78.66亿元。银华国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2024-01-03)以来超额回报为-34.4%,近一个月超额回报为-2.92%,管理人为银华基金公司,基金经理为马君。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600004566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2580472227","title":"【ETF动向】11月3日南方国证港股通创新药ETF基金涨2.03%,份额增加7600万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2580472227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580472227?lang=zh_cn&edition=full","pubTime":"2025-11-04 08:01","pubTimestamp":1762214487,"startTime":"0","endTime":"0","summary":"证券之星消息,11月3日,南方国证港股通创新药ETF基金(159297)涨2.03%,成交额2.27亿元。当日份额增加了7600万份,最新份额为13.65亿份,近20个交易日份额增加8.35亿份。当日资金净流入9400.57万元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为12.23亿元。南方国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2025-09-12)以来超额回报为-1.56%,近一个月超额回报为-1.13%,管理人为南方基金公司,基金经理为张其思 叶震南。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400005198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2578693630","title":"半年线支撑显现,港股通创新药ETF(520880)盘中再起溢价!行情拐点将至?","url":"https://stock-news.laohu8.com/highlight/detail?id=2578693630","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578693630?lang=zh_cn&edition=full","pubTime":"2025-10-27 11:41","pubTimestamp":1761536460,"startTime":"0","endTime":"0","summary":"10月27日,港股创新药延续回暖态势,恒瑞医药、君实生物、映恩生物-B、荣昌生物等多股涨超3%,恒生港股通创新药精选指数飘红于半年线上方。 作为跟踪该指数的代表性产品,港股通创新药ETF早盘红盘震荡,量能有所放大,不到半日成交超2.6亿元。盘中再起溢价,或有多头进场,此前10个交易日,累计逾2.9亿元逆行增仓。 技术面上看,港股通创新药ETF标的指数近日险守半年线关键位置,后续需要观测“跌破”还是“站稳”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-27/doc-infviaav2310772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520880"],"gpt_icon":0},{"id":"2578166534","title":"银华基金马君旗下银华国证港股通创新药ETF三季报最新持仓,重仓百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2578166534","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578166534?lang=zh_cn&edition=full","pubTime":"2025-10-27 07:20","pubTimestamp":1761520832,"startTime":"0","endTime":"0","summary":"证券之星消息,10月27日银华基金旗下马君管理的银华国证港股通创新药交易型开放式指数基金公布三季报,近1年净值增长率60.93%。与上一季度相比,该基金前十大重仓股新增科伦博泰生物-B,荣昌生物;并对百济神州增仓259.66万股,为该基金第一大重仓股;药明生物,亚盛医药-B等退出前十大重仓股;详细数据如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0307460666.USD","LU1303224171.USD","LU2328871848.SGD","06160","BK1161","LU1251922891.USD","LU1969619763.USD","BK0239","LU0588546209.SGD","LU1719994722.HKD","LU1770034418.SGD","BK1588","BK1583","520880","688235","BK1500"],"gpt_icon":0},{"id":"2577432333","title":"【ETF动向】10月22日银华国证港股通创新药ETF基金跌2.86%,份额增加1.02亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2577432333","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577432333?lang=zh_cn&edition=full","pubTime":"2025-10-23 07:30","pubTimestamp":1761175852,"startTime":"0","endTime":"0","summary":"证券之星消息,10月22日,银华国证港股通创新药ETF基金(159567)跌2.86%,成交额10.94亿元。当日份额增加了1.02亿份,最新份额为82.25亿份,近20个交易日份额减少1500万份。当日资金净流出7713.81万元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为69.45亿元。银华国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2024-01-03)以来超额回报为-34.88%,近一个月超额回报为-3.11%,管理人为银华基金公司,基金经理为马君。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300005254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2577838739","title":"景顺长城中证港股通创新药ETF基金经理变动:张晓南不再担任该基金基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2577838739","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577838739?lang=zh_cn&edition=full","pubTime":"2025-10-22 09:31","pubTimestamp":1761096669,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年10月22日,景顺长城中证港股通创新药ETF发布公告,张晓南不再担任该基金基金经理,离任日期为2025年10月22日,变更后景顺长城中证港股通创新药ETF的基金经理为金璜。截止2025年10月21日,景顺长城中证港股通创新药ETF净值为1.7831,较上一日上涨0.27%,近一年上涨73.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200008450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2577382042","title":"114亿美元!中国创新药BD新纪录!高弹性港股通创新药ETF(520880)热度飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2577382042","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577382042?lang=zh_cn&edition=full","pubTime":"2025-10-22 09:21","pubTimestamp":1761096060,"startTime":"0","endTime":"0","summary":"中国创新药重磅!最新消息,信达生物与武田制药达成114亿美元战略合作。 利好突袭,二级市场方面重点关注100%创新药研发标的——港股通创新药ETF。 行情方面,昨日,港股通创新药板块震荡回暖,港股通创新药ETF场内收涨1.21%终结两连跌,尾盘溢价飙升逾1%,显示买盘强劲。 资金面来看,港股通创新药ETF近期持续吸金,最近10个交易日内有7日均获净申购,金额合计1.76亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-22/doc-infutnct3559448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","159992","06978","520880"],"gpt_icon":0},{"id":"2577386901","title":"【ETF动向】10月21日易方达恒生港股通创新药ETF基金涨1.24%,份额增加1.31亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2577386901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577386901?lang=zh_cn&edition=full","pubTime":"2025-10-22 07:30","pubTimestamp":1761089440,"startTime":"0","endTime":"0","summary":"证券之星消息,10月21日,易方达恒生港股通创新药ETF基金(159316)涨1.24%,成交额6.72亿元。当日份额增加了1.31亿份,最新份额为24.45亿份,近20个交易日份额增加7.78亿份。当日资金净流入1.89亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为35.48亿元。易方达恒生港股通创新药ETF基金跟踪标的为恒生港股通创新药指数,成立(2025-03-18)以来超额回报为-7.15%,近一个月超额回报为0.01%,管理人为易方达基金公司,基金经理为成曦。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200005484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2577822463","title":"港股通创新药回暖,520880涨1.21%溢价飙升!基金经理:创新药行情或将重回“质量”驱动,龙头有望胜出","url":"https://stock-news.laohu8.com/highlight/detail?id=2577822463","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577822463?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:39","pubTimestamp":1761046740,"startTime":"0","endTime":"0","summary":"10月21日,港股通创新药板块震荡回暖,100%创新药研发标的——港股通创新药ETF午后稳定涨势,场内收涨1.21%终结两连跌。成份股荣昌生物、云顶新耀涨超4%,权重股石药集团、翰森制药跌1%有所拖累。 9月中旬以来,港股通创新药震荡走低,而创新药产业的态度和动作,成为波动行情中的“定心丸”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-21/doc-infusekp1333043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1574","520880","BK1161"],"gpt_icon":0},{"id":"2576076940","title":"医药资产又香了?近7亿资金增仓医疗ETF(512170)!港股通创新药ETF(520880)连日高溢价","url":"https://stock-news.laohu8.com/highlight/detail?id=2576076940","media":"新浪基金","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576076940?lang=zh_cn&edition=full","pubTime":"2025-10-19 20:39","pubTimestamp":1760877540,"startTime":"0","endTime":"0","summary":"AH医药资产随大市走低,不过多只代表性ETF场内高溢价,资金逢跌吸筹痕迹明显。 具体来看,A股最大医疗ETF重仓医疗器械及CXO,场内收跌2.39%,全天放量溢价,成交环比激增三成至6.87亿元,显示买盘势力强劲。 与A股医药核心标的一样,港股通创新药ETF全天溢价交易,且溢价幅度显著更大,溢价率一度飙升逾1%!近日该ETF资金面同样火热,近5日净流入逾1.28亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-10-19/doc-infumsea9108654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","159828","512170","BK1574","520880","09939","BK1161","159938"],"gpt_icon":0},{"id":"2576539777","title":"【ETF动向】10月16日南方国证港股通创新药ETF基金涨2.19%,份额增加1亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2576539777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576539777?lang=zh_cn&edition=full","pubTime":"2025-10-17 08:01","pubTimestamp":1760659274,"startTime":"0","endTime":"0","summary":"证券之星消息,10月16日,南方国证港股通创新药ETF基金(159297)涨2.19%,成交额1.7亿元。当日份额增加了1亿份,最新份额为8.84亿份。当日资金净流入1.09亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为8.19亿元。南方国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2025-09-12)以来超额回报为-3.98%,近一个月超额回报为-2.5%,管理人为南方基金公司,基金经理为张其思 叶震南。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700005490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2575762157","title":"第二波行情启动?高弹性港股通创新药ETF(520880)冲高3.6%!映恩生物-B、三生制药、康方生物集体飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2575762157","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575762157?lang=zh_cn&edition=full","pubTime":"2025-10-16 10:18","pubTimestamp":1760581080,"startTime":"0","endTime":"0","summary":"10月16日早盘,港股通创新药板块盘中快速走强,映恩生物-B领涨逾9%,三生制药涨超8%,康方生物、博安生物、君实生物等大幅续涨。 港股通创新药ETF100%布局创新药研发类公司,直线冲高逾3.6%,成交快速突破2亿元。值得关注的是,近日来520880资金面持续升温,此前4日连续吸金合计1.3亿元。 华福证券指出,ESMO等会议可能带来超预期数据读出,叠加Q4或有BD催化落地,预计四季度创新药或迎第二波行情。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"fc7ccc68210fffcf55d2ffc6613e5571","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-16/doc-inftzxps1316751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0348766576.USD","LU0417516902.SGD","09926","IE00B5MMRT66.SGD","LU0348767384.USD","LU0417516571.SGD","BK1161","LU2543165471.USD","BK1583","520880","LU0634319403.HKD","LU2476274308.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348825331.USD","LU0348783233.USD","HK0000252152.HKD","LU1794554557.SGD","LU0561508036.HKD","LU1961090484.USD","HK0000500386.USD","IE00BPRC5H50.USD","LU2399975544.HKD","LU2476274720.SGD","LU2488822045.USD","LU1720050803.USD","09606","HK0000252160.HKD","LU2778985437.USD","LU0417516738.SGD","BK1593","BK1574","LU0348784397.USD","LU0348735423.USD","LU0348827113.USD","01530"],"gpt_icon":0},{"id":"2575769910","title":"港股真香,齐刷刷上涨!港股ETF三剑客520560、513770、520880带头冲锋突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2575769910","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575769910?lang=zh_cn&edition=full","pubTime":"2025-10-16 09:08","pubTimestamp":1760576880,"startTime":"0","endTime":"0","summary":" 10月15日,港股ETF三剑客悉数反转突围,迎来上涨行情,涉及港股大盘及港股创新药、港股互联网等港股明星板块。港股AI核心工具——港股互联网ETF场内价格盘中一度涨逾2.6%,近5日港股互联网ETF资金累计净流入1.3亿元,港股+AI魅力尽显。截至10月15日,港股通创新药ETF近20个交易日内累计吸金近7亿元。 全市场首只香港大盘30ETF盘中大幅溢价,一度涨超2.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-16/doc-inftzxpt2715395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["513770","BK4588","520880","520560","BK4550","FDN","BK4585"],"gpt_icon":0},{"id":"2574974934","title":"AH医药再陷调整,医疗ETF止步三连阳,港股通创新药ETF(520880)失守所有均线,该抄底还是离场?","url":"https://stock-news.laohu8.com/highlight/detail?id=2574974934","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574974934?lang=zh_cn&edition=full","pubTime":"2025-10-12 19:47","pubTimestamp":1760269620,"startTime":"0","endTime":"0","summary":"周五,A股、港股市场同频震荡,沪指失守3900点,创指大跌4.55%,恒生指数收出5连阴。大盘承压,AH医药板块全线走低。 A股医疗板块低开低走,CXO跌幅靠前,巨头药明康德领跌7.2%,规模最大医疗ETF场内跌2.03%止步三连阳,盘中下穿3根均线,交投仍在高位,全天成交6.4亿元。港股通创新药ETF100%布局创新药研发类公司,下跌区间宽幅溢价,最高飙逾1%,显示买盘尤为强劲。截至10月9日,520880近20日累计吸金超6.75亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-12/doc-inftruik6008282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159828","520880","159938","BK1574","09939","512170","BK1515"],"gpt_icon":0},{"id":"2574179972","title":"风险还是机遇?AH医药集体杀跌!药明康德重挫,医疗ETF下穿3根均线!创新药反攻未果,520880溢价飙逾1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574179972","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574179972?lang=zh_cn&edition=full","pubTime":"2025-10-10 20:50","pubTimestamp":1760100600,"startTime":"0","endTime":"0","summary":"周五,A股、港股市场同频震荡,沪指失守3900点,创指大跌4.55%,恒生指数收出5连阴。大盘承压,AH医药板块全线走低。 A股医疗板块低开低走,CXO跌幅靠前,巨头药明康德领跌7.2%,规模最大医疗ETF场内跌2.03%止步三连阳,盘中下穿3根均线,交投仍在高位,全天成交6.4亿元。港股通创新药ETF100%布局创新药研发类公司,下跌区间宽幅溢价,最高飙逾1%,显示买盘尤为强劲。截至10月9日,520880近20日累计吸金超6.75亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-10/doc-inftmnmf1183107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0052750758.USD","LU0708995583.HKD","LU1979443071.USD","LU2488822045.USD","BK1576","LU1969619763.USD","LU1808992512.USD","02359","09939","520880","LU2495084118.USD","LU2125910500.SGD","512170","BK1583","LU1997245177.USD","LU2242644610.SGD","603259","159938","LU0320764599.SGD","BK1161","LU1046422090.SGD","06978","BK1515","159992","LU0456842615.SGD","LU2328871848.SGD","LU1934453819.USD","BK1141","LU1997245094.SGD","159828","LU1997244956.HKD","BK1574","LU2045819591.USD","BK0216"],"gpt_icon":1},{"id":"2574115577","title":"【ETF动向】10月9日易方达恒生港股通创新药ETF基金跌1.26%,份额增加1亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2574115577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574115577?lang=zh_cn&edition=full","pubTime":"2025-10-10 08:01","pubTimestamp":1760054480,"startTime":"0","endTime":"0","summary":"证券之星消息,10月9日,易方达恒生港股通创新药ETF基金(159316)跌1.26%,成交额5.86亿元。当日份额增加了1亿份,最新份额为19.25亿份,近20个交易日份额增加7.28亿份。当日资金净流入8817.78万元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为29.77亿元。易方达恒生港股通创新药ETF基金跟踪标的为恒生港股通创新药指数,成立(2025-03-18)以来超额回报为-7.55%,近一个月超额回报为0.13%,管理人为易方达基金公司,基金经理为成曦。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000005026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765064606920,"stockEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.1672}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"港股通创新药ETF(520880)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供港股通创新药ETF(520880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"港股通创新药ETF,520880,港股通创新药ETF股票,港股通创新药ETF股票老虎,港股通创新药ETF股票老虎国际,港股通创新药ETF行情,港股通创新药ETF股票行情,港股通创新药ETF股价,港股通创新药ETF股市,港股通创新药ETF股票价格,港股通创新药ETF股票交易,港股通创新药ETF股票购买,港股通创新药ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"港股通创新药ETF(520880)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供港股通创新药ETF(520880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}